Skip to main content

Table 4 Summary of literature on radiation therapy as a bridge to transplantation in HCC

From: Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series

Study, year(ref.)

Pre-operative radiotherapy

Liver transplantation

No. of patients /lesions

Child–Pugh class

Dose (Gy)/no. of fractions

Infield control rate (%)

Toxicity ≥ grade 3/RILD

No. of patient

Median time to LT (months)

Pathologic response

Post-transplant outcome

Median follow-up (months)

Sandroussi, 2010 [8]

10/10

A: 40%

B: 50%

C: 10%

33/1–6

100%

0/0

5

5.2

SpR: 3 (60%)

MpR: 1 (20%)

NpR: 1 (20%)

6-month RFS: 70%

6

Andolino, 2011 [9]

60/NA

A: 60%

B: 40%

40–44/3

NA

21/NA

23

7

NA

2-year OS: 96%

2-year PFS: 69%

27

Katz, 2011 [10]

18/21

A: 17%

B: 44%

C: 22%

NA:17%

50/10

100%

1/0

11

6

CpR: 2 (18.1%)

SpR: 3 (27.2%)

MpR 4 (36.6%)

NpR: 2 (18.1%)

1 liver recurrence

10 alive with NED

19.6

O'Connor, 2012 [11]

10/11

A: 70%

B: 20%

C: 10%

51/3

100%

0/0

10

3.8

NpR: 3 (30%)

5-year OS: 100%

5-year DFS: 100%

62

Guarneri, 2016 [12]

8/13

A: 62%

B: 38%

36–48/3–5

100%

0/1

8

3.2

CpR: 8 (61.5%)

SpR: 1 (7.7%)

MpR: 2 (15.3%)

NpR: 2 (15.3%)

No liver recurrence

7 alive with NED

9.6

Moore, 2017 [13]

23/NA

A: 57%

B: 43%

30/5

48/4

54/3

100%

0/1

11

4.8

CpR: 3 (27.3%)

SpR: 6 (54.5%)

MpR: 2 (18.2%)

Median OS: not reached

Median PFS: not reached

12

Mannina, 2017 [14]

38/51

A: 45%

B: 55%

36–45/3–5

NA

NA/NA

38

8.8

CpR: 45%

1, 2, 3, 5-year OS: 92%, 86%, 77%, 73%

1, 2, 3, 5-year DFS: 91%, 85%, 74%, 74%

58

Gresswell, 2018 [15]

12/17

B: 58%

C: 42%

40/5

100%

0/0

11

5

CpR: 46%

1,2,3,4-year OS: 91%, 91%, 68%, 57%

40

Sapisochin, 2017 [16]

36/NA

A: 61%

B: 39%

36/6

NA

NA/NA

30

5.2

CpR: 4 (13.3%)

SpR: 12 (40%)

MpR: 11 (36.7%)

NpR: 3 (10%)

1,3,5-year OS: 83%, 75%,75%

29.6

Present series

14/26

A: 79%

B: 14%

C: 7%

45/5

100%

4/1

14

8.4

CpR: 3 (27.3%)

SpR: 3 (27.3%)

MpR: 5 (45.4%)

Median OS: 37.8 months

Median RFS: 18.3 months

30.2

  1. CpR, complete pathologic response; LT, liver transplantation; MpR, minimal pathological response; NA, not available; NpR, no pathologic response; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; RILD, radiation-induced liver disease; SpR, significant pathologic response